Atorvastatin decreases elevated soluble CD40L in subjects at high cardiovascular risk. Atorvastatin on inflammatory markers study: a substudy of ACTFAST.

Luis M. Blanco-Colio; Jose L. Martín-Ventura; Eduardo de Teresa; Csaba Farsang; Allan Gaw; Gianfranco Gensini; Lawrence A. Leiter; Anatoly Langer; Pierre Martineau; Jesús Egido

Atorvastatin decreases elevated soluble CD40L in subjects at high cardiovascular risk. Atorvastatin on inflammatory markers study: a substudy of ACTFAST.

Luis M. Blanco-Colio, Jose L. Martín-Ventura, Eduardo de Teresa, Csaba Farsang, Allan Gaw, Gianfranco Gensini, Lawrence A. Leiter, Anatoly Langer, Pierre Martineau, Jesús Egido

Fondazione Don Carlo Gnocchi Onlus

Research output: Contribution to journal › Article

Abstract

The CD40/CD40 ligand plays a role in the inflammatory and prothrombotic processes in atherosclerosis. We analyzed whether short-term treatment with atorvastatin affects soluble CD40 ligand (sCD40L) plasma levels in subjects at high cardiovascular risk. sCD40L plasma concentrations were measured in 852 subjects from the Atorvastatin on Inflammatory Markers (AIM) Study, a 12-week prospective multicenter, open-label trial which enrolled statin-free subjects with coronary heart disease (CHD), CHD-equivalent (diabetes, peripheral vascular disease, or cerebrovascular disease), or a 10-year CHD risk >20%. Subjects were assigned to atorvastatin (10-80 mg/day) based on LDL-C at screening. Overall, sCD40L levels were not different in patients at high cardiovascular risk compared with healthy subjects. When sCD40L levels were divided in quartiles, patients in the highest quartile (N=213) had higher sCD40L concentrations than age- and gender-matched healthy subjects (N=29) (P

Original language	English
Journal	Kidney international. Supplement
Issue number	111
Publication status	Published - Dec 2008

ASJC Scopus subject areas

Nephrology

Access to Document

Fingerprint Dive into the research topics of 'Atorvastatin decreases elevated soluble CD40L in subjects at high cardiovascular risk. Atorvastatin on inflammatory markers study: a substudy of ACTFAST.'. Together they form a unique fingerprint.

Cite this

Blanco-Colio, L. M., Martín-Ventura, J. L., de Teresa, E., Farsang, C., Gaw, A., Gensini, G., Leiter, L. A., Langer, A., Martineau, P., & Egido, J. (2008). Atorvastatin decreases elevated soluble CD40L in subjects at high cardiovascular risk. Atorvastatin on inflammatory markers study: a substudy of ACTFAST. Kidney international. Supplement, (111).

Atorvastatin decreases elevated soluble CD40L in subjects at high cardiovascular risk. Atorvastatin on inflammatory markers study : a substudy of ACTFAST. / Blanco-Colio, Luis M.; Martín-Ventura, Jose L.; de Teresa, Eduardo; Farsang, Csaba; Gaw, Allan; Gensini, Gianfranco; Leiter, Lawrence A.; Langer, Anatoly; Martineau, Pierre; Egido, Jesús.

In: Kidney international. Supplement, No. 111, 12.2008.

Research output: Contribution to journal › Article

Blanco-Colio, Luis M. ; Martín-Ventura, Jose L. ; de Teresa, Eduardo ; Farsang, Csaba ; Gaw, Allan ; Gensini, Gianfranco ; Leiter, Lawrence A. ; Langer, Anatoly ; Martineau, Pierre ; Egido, Jesús. / Atorvastatin decreases elevated soluble CD40L in subjects at high cardiovascular risk. Atorvastatin on inflammatory markers study : a substudy of ACTFAST. In: Kidney international. Supplement. 2008 ; No. 111.

@article{50ef5f989697414abdad8f4581d54dec,

title = "Atorvastatin decreases elevated soluble CD40L in subjects at high cardiovascular risk. Atorvastatin on inflammatory markers study: a substudy of ACTFAST.",

abstract = "The CD40/CD40 ligand plays a role in the inflammatory and prothrombotic processes in atherosclerosis. We analyzed whether short-term treatment with atorvastatin affects soluble CD40 ligand (sCD40L) plasma levels in subjects at high cardiovascular risk. sCD40L plasma concentrations were measured in 852 subjects from the Atorvastatin on Inflammatory Markers (AIM) Study, a 12-week prospective multicenter, open-label trial which enrolled statin-free subjects with coronary heart disease (CHD), CHD-equivalent (diabetes, peripheral vascular disease, or cerebrovascular disease), or a 10-year CHD risk >20%. Subjects were assigned to atorvastatin (10-80 mg/day) based on LDL-C at screening. Overall, sCD40L levels were not different in patients at high cardiovascular risk compared with healthy subjects. When sCD40L levels were divided in quartiles, patients in the highest quartile (N=213) had higher sCD40L concentrations than age- and gender-matched healthy subjects (N=29) (P",

author = "Blanco-Colio, {Luis M.} and Mart{\'i}n-Ventura, {Jose L.} and {de Teresa}, Eduardo and Csaba Farsang and Allan Gaw and Gianfranco Gensini and Leiter, {Lawrence A.} and Anatoly Langer and Pierre Martineau and Jes{\'u}s Egido",

year = "2008",

month = dec,

language = "English",

journal = "Kidney International, Supplement",

issn = "0098-6577",

publisher = "Wiley-Blackwell",

number = "111",

}

TY - JOUR

T1 - Atorvastatin decreases elevated soluble CD40L in subjects at high cardiovascular risk. Atorvastatin on inflammatory markers study

T2 - a substudy of ACTFAST.

AU - Blanco-Colio, Luis M.

AU - Martín-Ventura, Jose L.

AU - de Teresa, Eduardo

AU - Farsang, Csaba

AU - Gaw, Allan

AU - Gensini, Gianfranco

AU - Leiter, Lawrence A.

AU - Langer, Anatoly

AU - Martineau, Pierre

AU - Egido, Jesús

PY - 2008/12

Y1 - 2008/12

N2 - The CD40/CD40 ligand plays a role in the inflammatory and prothrombotic processes in atherosclerosis. We analyzed whether short-term treatment with atorvastatin affects soluble CD40 ligand (sCD40L) plasma levels in subjects at high cardiovascular risk. sCD40L plasma concentrations were measured in 852 subjects from the Atorvastatin on Inflammatory Markers (AIM) Study, a 12-week prospective multicenter, open-label trial which enrolled statin-free subjects with coronary heart disease (CHD), CHD-equivalent (diabetes, peripheral vascular disease, or cerebrovascular disease), or a 10-year CHD risk >20%. Subjects were assigned to atorvastatin (10-80 mg/day) based on LDL-C at screening. Overall, sCD40L levels were not different in patients at high cardiovascular risk compared with healthy subjects. When sCD40L levels were divided in quartiles, patients in the highest quartile (N=213) had higher sCD40L concentrations than age- and gender-matched healthy subjects (N=29) (P

AB - The CD40/CD40 ligand plays a role in the inflammatory and prothrombotic processes in atherosclerosis. We analyzed whether short-term treatment with atorvastatin affects soluble CD40 ligand (sCD40L) plasma levels in subjects at high cardiovascular risk. sCD40L plasma concentrations were measured in 852 subjects from the Atorvastatin on Inflammatory Markers (AIM) Study, a 12-week prospective multicenter, open-label trial which enrolled statin-free subjects with coronary heart disease (CHD), CHD-equivalent (diabetes, peripheral vascular disease, or cerebrovascular disease), or a 10-year CHD risk >20%. Subjects were assigned to atorvastatin (10-80 mg/day) based on LDL-C at screening. Overall, sCD40L levels were not different in patients at high cardiovascular risk compared with healthy subjects. When sCD40L levels were divided in quartiles, patients in the highest quartile (N=213) had higher sCD40L concentrations than age- and gender-matched healthy subjects (N=29) (P

UR - http://www.scopus.com/inward/record.url?scp=61549117198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61549117198&partnerID=8YFLogxK

M3 - Article

C2 - 19034329

AN - SCOPUS:61549117198

JO - Kidney International, Supplement

JF - Kidney International, Supplement

SN - 0098-6577

IS - 111

ER -